Neurocrine Delays Indiplon Resubmission To Run Confirmatory Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Adding an insurance study to the NDA package means Neurocrine could finally see income from the insomnia aid in late 2008.
You may also be interested in...
Neurocrine Resubmits Immediate-Release Indiplon
Sleep aid could at last reach market late in 2008.
Neurocrine Resubmits Immediate-Release Indiplon
Sleep aid could at last reach market late in 2008.
Silenor’s Bleary Regulatory Timeline May Clear Up
Somaxon’s sleep aid is on track for a third-quarter NDA submission; partnering deal also expected during 2007.